All Oncology News

LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

The FDA has granted de novo marketing authorization to the PGDx elio plasma focus Dx pan–solid tumor liquid biopsy test.

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.

Researchers at the Mayo Clinic found that patients with BCP-ALL who lacked the Philadelphia chromosome and were in remission showed higher survival rates with blinatumomab plus chemotherapy.

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

The FDA has granted accelerated approval to afamitresgene autoleucel for select patients with pretreated unresectable or metastatic synovial sarcoma.

The FDA granted an orphan drug designation to the combination of avutometinib and defactinib for use as a potential therapeutic option in patients with pancreatic cancer.

The FDA has approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer.

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

Teh Lin, PhD, DABR, FAAPM, of Fox Chase Cancer Center, has been named a Fellow of the American Association of Physicists in Medicine.

Soquelitinib has received fast track designation from the FDA for patients with relapsed or refractory peripheral T-cell lymphoma after at least 2 lines of systemic therapy.

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Evorpacept plus TRP generated clinically meaningful, robust, and durable responses in patients with previously treated HER2-positive gastric or GEJ cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.

Steven Chen, PhD, and colleagues identified a 10-gene biomarker that may predict benefit with adjuvant chemotherapy in stage II/III colon cancer.

VCN-01 has received rare pediatric drug designation from the FDA for patients with retinoblastoma.

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.